NDAIntravesical, UreteralSolution
Approved
Apr 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CYSTO-CONRAY (iothalamate meglumine) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1972.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTO-CONRAY (iothalamate meglumine) is a contrast medium containing iodine used for retrograde urography and visualization of the lower urinary tract and ureters. Administered intravesically or uretherally via sterile catheter, it provides radiodensity for radiographic imaging of urological structures. The drug's mechanism relies on iodine's high atomic weight to produce sufficient contrast for diagnostic visualization.
LOE Approaching
As an aging diagnostic contrast agent approaching loss of exclusivity with minimal competitive pressure data, the brand team is likely small and focused on maintaining market access in specialized urology centers.
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYSTO-CONRAY offers limited career growth opportunities given its mature, low-growth lifecycle stage and minimal linked job postings. Roles on this product are primarily focused on market maintenance, compliance, and operational efficiency rather than expansion or innovation.
Product Manager (Diagnostics)
Worked on CYSTO-CONRAY at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.